Spencer Group were delighted to attend the 17th edition of the Scrip Awards on the 2nd December, hosted live in London. The Scrip Awards honours the outstanding accomplishments of those improving human healthcare worldwide…
We are excited to be speaking to Steve Geffon, a highly experienced commercial lead in the eclinical and services market. Steve is the CCO of Science37, an organisation with over 6 years in virtual/decentralised trials.
What are the possible implications of Covid-19 on the biopharmaceutical and the wider pharmaceutical markets?
Steve Kent is currently Non-Executive Chairman at Phlexglobal, 4ways and Pharmaspectra, as well as Non-Executive Director at Imagen Therapeutics. During Steve’s time as an executive
Steve Powell is a renowned, international expert with a career spanning over 30 years within pharmaceutical technology. He has worked for organisations such as GSK and Phase Forward and now has a number of NED and Chair positions
Neil Rotherham is a serial entrepreneur with over 25 year’s experience in the pharmaceutical and medical technology markets with proven experience of running and building businesses in the UK and USA.
Geoff Webster is Managing Director of CEG Digital, a division of Cambridge Education Group specialising in partnering with high quality UK, EU, US and Australian universities to enable the delivery of part time, flexible
Tim Davis, CEO of Raremark, a real world evidence/data organisation in the rare diseases space, discusses the possible implications coronavirus will have on the wider
Experienced entrepreneur Tim Davis, one of the founders and ex-CEO of Exco in Touch before its strategic sale to ERT, discusses his experience in founding an eclinical business